Albertsen P C, Fryback D G, Storer B E, Kolon T F, Fine J
Department of Surgery, University of Connecticut Health Center, Farmington, USA.
J Urol. 1996 Jul;156(1):127-32.
We evaluated 3 indexes used to assess patient co-morbidities to determine whether they could predict mortality among men with clinically localized prostate cancer.
We measured the impact of co-morbidity classifications on all cause mortality using a parametric proportional hazards model based on a retrospective cohort analysis.
Each index tested is a highly significant predictor of mortality for patients dying of nonprostate cancer related causes after adjusting for age and Gleason score.
Each co-morbidity index provides significant, independent predictive information concerning patient mortality beyond that provided by age, Gleason score and clinical stage alone.
我们评估了用于评估患者合并症的3项指标，以确定它们是否能够预测临床局限性前列腺癌男性患者的死亡率。
我们基于回顾性队列分析，采用参数化比例风险模型测量合并症分类对全因死亡率的影响。
在对年龄和Gleason评分进行校正后，每项测试指标都是死于非前列腺癌相关原因患者死亡率的高度显著预测因子。
除了年龄、Gleason评分和临床分期单独提供的信息外，每项合并症指标都能提供有关患者死亡率的显著、独立的预测信息。
